AstraZeneca, Accenture, Amazon Web Services (AWS), and Clalit Health Services - the largest healthcare organization in Israel - have selected six startups to participate in BeyondBio SCALE. Among them is Yeda spinoff company, “Curesponse” - a unique, innovative and focused test combining tissue reactions to various drugs with rapid genomic sequencing for optimal cancer treatment adjustment.

Developed at Weizmann Institute of Science, the proprietary lab assay keeps tissue samples viable for over a week while preserving a functional tumor microenvironment (TME) - the basis for Curesponse's cResponse platform.

The combination enables cResponse to deliver a clinical test based on ten different combinations of drugs/drug combinations across a range of therapeutic modality spectrums (chemo, targeted biologics, immunotherapy) to patients, oncologists, and pharmaceutical partners in 2 weeks.

Congratulations to the team at Curesponse, and good luck in the BeyondBio SCALE program >>